Stage_IIB_osteogenic_sarcoma._Two_hundred_seventy-one_consecutive_patients_treated_from_1976_through_1986_were_reviewed_to_estimate_long-term_survival._Disease-free_survival_for_the_entire_cohort_was_77%_at_five_years_and_74%_at_ten_years._Humeral_lesions_had_the_best_probability_of_survival_(84%_at_ten_years),_followed_by_tibial_lesions_(81%)_and_femoral_lesions_(67%)._Histologic_response_to_preoperative_chemotherapy_was_the_strongest_predictor_of_outcome._Those_with_little_response_had_a_survival_estimate_of_54%_at_ten_years_as_compared_to_68%_for_partial_responders_and_approximately_90%_for_complete_responders._Local_recurrence_was_seen_in_6.6%_and_was_associated_with_an_adverse_effect_on_survival._Only_two_of_the_18_patients_with_local_recurrence_have_been_rendered_long-term_disease-free_survivors.